Multiple Myeloma Hub
Ein Podcast von Scientific Education Support
57 Folgen
-
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
Vom: 8.7.2020 -
Melphalan flufenamide (melflufen) + novel agents for RRMM
Vom: 8.7.2020 -
Isatuximab plus KRd for high-risk NDMM
Vom: 24.6.2020 -
Novel approaches in multiple myeloma: what is unique about CELMoDs?
Vom: 24.6.2020 -
Hot topics in MM: quadruplets and anti-BCMA therapy
Vom: 24.6.2020 -
Genomics of high-risk myeloma
Vom: 23.6.2020 -
The association between the diversity of the oral microbiome and PFS
Vom: 22.6.2020 -
Novel approaches in multiple myeloma: BFCR4350A
Vom: 18.6.2020 -
Update from CARTITUDE-1 | What's new since ASH?
Vom: 8.6.2020 -
Novel approaches in multiple myeloma: TAK-079
Vom: 4.6.2020 -
Should we use KRd or VRd for patients with NDMM?
Vom: 4.6.2020 -
What is the optimal treatment for bone lesions, including patients with renal insufficiency?
Vom: 3.6.2020 -
Recent advances in our understanding of myeloma progression
Vom: 2.6.2020 -
Quadruplet combinations in transplant-ineligible NDMM: isatuximab + Vd + cyclo or len
Vom: 1.6.2020 -
How I treat elderly patients with NDMM
Vom: 28.5.2020 -
Understanding resistance mechanisms to current standard of care and how to overcome them
Vom: 19.5.2020 -
What is plasma cell leukemia and what are the latest advances in treatment?
Vom: 15.5.2020
Guided by an international Steering Committee of world experts in Multiple Myeloma (MM), the MM Hub is a global online resource providing key information on Multiple Myeloma for hematologists, oncologists and researchers, run in collaboration with the European School of Haematology (ESH). Our mission is to provide the latest global up-to-date clinical guidance in Multiple Myeloma, through a comprehensive coverage of evidence-based literature, drug approvals, case studies, expert opinions and international congress reports. Hosted on Acast. See acast.com/privacy for more information.
